NRx Pharmaceuticals, Inc.
NASDAQ:NRXP
3.51 (USD) • At close January 6, 2025
Overzicht | Financiële gegevens
Bedrijfsnaam | NRx Pharmaceuticals, Inc. |
Symbool | NRXP |
Munteenheid | USD |
Prijs | 3.51 |
Beurswaarde | 42,450,291 |
Dividendpercentage | 0% |
52-weken bereik | 1.1 - 7.33 |
Industrie | Biotechnology |
Sector | Healthcare |
CEO | Mr. Stephen H. Willard Esq. |
Website | https://www.nrxpharma.com |
An error occurred while fetching data.
Over NRx Pharmaceuticals, Inc.
NRX Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. Its products include ZYESAMI, an investigational drug that has completed a Phase IIb/III clinical study for COVID-19 related respiratory failure; and NRX-100 and NRX-101 oral therapeutics for the
Vergelijkbare Aandelen
Financiële Gegevens
Cijfers zijn in miljoenen (USD)
Cijfers zijn in miljoenen (USD)